Diagnosis & Your Test Results: The Path to Confirmation
Last updated:
Acromegaly diagnosis requires a three-step process: an IGF-1 blood test, an oral glucose tolerance test (OGTT) to measure your growth hormone (GH) nadir, and a pituitary MRI. These tests confirm if a tumor is producing excess hormone and determine its exact size and location.
Key Takeaways
- • IGF-1 is the most reliable initial blood test for acromegaly because it remains stable throughout the day.
- • An oral glucose tolerance test (OGTT) confirms the diagnosis if your growth hormone levels fail to drop below 0.4 µg/L.
- • A gadolinium-enhanced MRI is used to locate the pituitary tumor and determine if it is a microadenoma or a larger macroadenoma.
- • The Knosp grade on your MRI report helps your surgeon understand how far the tumor has spread and the likelihood of successful removal.
Confirming a diagnosis of acromegaly involves more than just a single blood test. Because your hormones naturally fluctuate throughout the day, doctors use “dynamic” testing to see how your body responds to specific triggers [1]. This process usually follows a three-step path: screening, confirmation, and imaging.
Step 1: The IGF-1 Screening
The first step is measuring Insulin-like Growth Factor 1 (IGF-1) [1]. Unlike Growth Hormone (GH), which pulses up and down, IGF-1 levels stay relatively stable in your blood, making it the most reliable “snapshot” of your average hormone activity [2].
- Age and Sex Matter: Your “normal” IGF-1 level depends heavily on how old you are and your sex [1]. A level that is healthy for a teenager would be dangerously high for a 50-year-old. When you look at your lab report, ensure your result is being compared to the reference range for your specific age group [1].
- Interferences: Conditions like liver disease, kidney failure, or poorly controlled diabetes can sometimes cause a “false low” IGF-1, even if acromegaly is active [2][3].
Step 2: The Sugar Water Test (OGTT)
To confirm the diagnosis, doctors use the Oral Glucose Tolerance Test (OGTT), often called the “gold standard” [4]. During this test, you will drink a standardized, highly concentrated glucose (sugar) drink. The medical team will then draw your blood multiple times over a period of about two hours to see how your hormones react. In a healthy body, drinking a high-sugar solution causes the pituitary gland to stop making Growth Hormone [4]. In acromegaly, the tumor ignores the sugar and continues to pump out GH [1].
- The GH Nadir: This is the lowest level your Growth Hormone reaches during the test.
- The Threshold: Using modern, highly sensitive tests, a GH nadir of less than 0.4 µg/L is generally considered a normal result that “rules out” active acromegaly [4][5]. If your GH stays above this level, it confirms the tumor is producing hormone autonomously [1].
Step 3: Pituitary MRI & The Knosp Grade
Once the blood tests confirm the hormone excess, a gadolinium-enhanced MRI is used to find the tumor [6]. Gadolinium is a contrast dye that helps the tumor stand out from the normal pituitary gland [7].
Tumor Size
Your report will likely classify the tumor based on its size:
- Microadenoma: Less than 10 millimeters (mm) [6].
- Macroadenoma: 10 millimeters or larger [6]. Macroadenomas are more common in acromegaly and may require more complex treatment if they press on nearby structures like the optic nerves [8].
Understanding the Knosp Grade
The Knosp scale is a grading system (0 to 4) that tells your surgeon how far the tumor has spread sideways into a nearby area called the cavernous sinus [9].
- Grades 0, 1, and 2: These are considered “non-invasive.” The tumor is contained or only slightly touching nearby structures. These usually have higher rates of successful surgical removal [10][9].
- Grades 3 and 4: These indicate the tumor has “invaded” or wrapped around the internal carotid artery [9]. While still treatable, these higher grades are more challenging for surgeons to remove completely [11][12].
Knowing these specific terms—GH nadir, macroadenoma, and Knosp grade—will help you have a much more detailed conversation with your endocrinologist and surgeon about your treatment plan.
Read next: Standard of Care Treatment: Surgery & Medical Therapies
Frequently Asked Questions
What is the first test used to diagnose acromegaly?
Why do I need to take the sugar water test (OGTT)?
What does GH nadir mean on my lab report?
What is a Knosp grade on an MRI report?
Can other conditions affect my IGF-1 test results?
Questions for Your Doctor
- • Was my IGF-1 result compared against a reference range adjusted specifically for my age and sex?
- • What was my exact GH nadir (lowest point) during the sugar water test? Was it below 0.4 µg/L?
- • Does my MRI report mention a Knosp grade, and what does that mean for the success rate of my surgery?
- • Is my tumor a microadenoma or a macroadenoma, and is it touching or pressing on my optic nerves?
- • Are there any conditions I have, like diabetes or liver issues, that might have made my IGF-1 result lower than it actually is?
Questions for You
- • Do I have my lab results in front of me so I can look for the terms 'IGF-1' and 'GH nadir'?
- • Have I checked my MRI report for the size of the tumor in millimeters (mm)?
- • How did I feel during the Oral Glucose Tolerance Test? Did the medical team explain why they were taking multiple blood samples?
- • Am I aware of any other health issues I have that might affect my hormone levels, such as liver or kidney problems?
Want personalized information?
Type your question below to get evidence-based answers tailored to your situation.
References
- 1
Biochemical following-up of treated acromegaly. Limitations of the current determinations of IGF-I and perspective.
Granada ML
Minerva endocrinologica 2019; (44(2)):143-158 doi:10.23736/S0391-1977.18.02922-X.
PMID: 30311754 - 2
Acromegaly presenting with low insulin-like growth factor-1 levels and diabetes: a case report.
Wijayaratne DR, Arambewela MH, Dalugama C, et al.
Journal of medical case reports 2015; (9()):241 doi:10.1186/s13256-015-0736-z.
PMID: 26514337 - 3
Acromegaly presenting with normal insulin-like growth factor-1 levels in a patient with advanced liver cirrhosis.
Kilcoyne C, Burke K, O'Reilly MW, et al.
BMJ case reports 2026; (19(2)) doi:10.1136/bcr-2025-266505.
PMID: 41713883 - 4
Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?
Dobri G, Niwattisaiwong S, Bena JF, et al.
Endocrine 2019; (64(1)):139-146 doi:10.1007/s12020-018-1805-z.
PMID: 30415402 - 5
Value of Early Post-Operative Growth Hormone Testing in Predicting Long-Term Remission and Residual Disease after Transsphenoidal Surgery for Acromegaly.
Wang YY, Waqar M, Abou-Zeid A, et al.
Neuroendocrinology 2022; (112(4)):345-357 doi:10.1159/000517476.
PMID: 34052822 - 6
Diagnosis and Treatment of Acromegaly: An Update.
Ershadinia N, Tritos NA
Mayo Clinic proceedings 2022; (97(2)):333-346 doi:10.1016/j.mayocp.2021.11.007.
PMID: 35120696 - 7
Rethinking MRI Protocols for Pituitary Microadenomas: Prioritizing Non-Contrast Imaging for Safe Follow-Up.
Zarei F, Nematollahi F, Jalil A, et al.
Tomography (Ann Arbor, Mich.) 2025; (11(9)) doi:10.3390/tomography11090105.
PMID: 41003488 - 8
Adenoma size and postoperative IGF-1 levels predict surgical outcomes in acromegaly patients: results of the Swiss Pituitary Registry (SwissPit).
Kempf J, Schmitz A, Meier A, et al.
Swiss medical weekly 2018; (148()):w14653.
PMID: 30141524 - 9
Predicting early post-operative remission in pituitary adenomas: evaluation of the modified knosp classification.
Buchy M, Lapras V, Rabilloud M, et al.
Pituitary 2019; (22(5)):467-475 doi:10.1007/s11102-019-00976-6.
PMID: 31286328 - 10
Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis.
Briceno V, Zaidi HA, Doucette JA, et al.
Neurological research 2017; (39(5)):387-398 doi:10.1080/01616412.2017.1296653.
PMID: 28301972 - 11
Machine learning in predicting early remission in patients after surgical treatment of acromegaly: a multicenter study.
Qiao N, Shen M, He W, et al.
Pituitary 2021; (24(1)):53-61 doi:10.1007/s11102-020-01086-4.
PMID: 33025547 - 12
Experience of Endoscopic Endonasal Approach for 803 Pituitary Tumors With Cavernous Sinus Invasion.
Zhu H, Li C, Gui S, et al.
The Journal of craniofacial surgery 2022; (33(2)):e118-e122 doi:10.1097/SCS.0000000000008049.
PMID: 34334752
This page explains acromegaly diagnostic testing and terminology for educational purposes. Always consult your endocrinologist and neurosurgeon to interpret your specific lab results and MRI reports.
Stay up to date
Get notified when new research about Acromegaly is published.
No spam. Unsubscribe anytime.